{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urinary+Tract+Disease&page=2",
    "query": {
      "condition": "Urinary Tract Disease",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urinary+Tract+Disease&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T17:08:07.753Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00561093",
      "title": "Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypoalbuminemia",
        "Protein-energy Malnutrition",
        "Inflammation",
        "Oxidative Stress",
        "Chronic Kidney Disease (CKD) Hemodialysis"
      ],
      "interventions": [
        {
          "name": "pentoxiphylline",
          "type": "DRUG"
        },
        {
          "name": "Nepro",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "anti-inflammatory module (similar to Oxepa)",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo pill imitating pentoxiphylline",
          "type": "DRUG"
        },
        {
          "name": "Placebo to imitate Nepro",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo to imitate anti-inflammatory module (similar to Oxepa)",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 93,
      "start_date": "2008-02",
      "completion_date": "2011-05",
      "has_results": false,
      "last_update_posted_date": "2015-05-21",
      "last_synced_at": "2026-07-23T17:08:07.753Z",
      "location_count": 2,
      "location_summary": "Irvine, California • Torrance, California",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00561093"
    },
    {
      "nct_id": "NCT04994522",
      "title": "A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "End Stage Renal Disease",
        "Renal Impairment"
      ],
      "interventions": [
        {
          "name": "Belzutifan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 14,
      "start_date": "2022-07-12",
      "completion_date": "2024-04-11",
      "has_results": true,
      "last_update_posted_date": "2025-04-06",
      "last_synced_at": "2026-07-23T17:08:07.753Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04994522"
    },
    {
      "nct_id": "NCT00234039",
      "title": "S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 58,
      "start_date": "2006-11",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2016-01-08",
      "last_synced_at": "2026-07-23T17:08:07.753Z",
      "location_count": 98,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Leesburg, Florida + 56 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Leesburg",
          "state": "Florida"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00234039"
    },
    {
      "nct_id": "NCT00087828",
      "title": "Identification of the Cranberry Juice Compounds That Prevent Urinary Tract Infections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Urinary Tract Infections"
      ],
      "interventions": [
        {
          "name": "Cranberry juice cocktail",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Center for Complementary and Integrative Health (NCCIH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 64 Years · Female only"
      },
      "enrollment_count": 5,
      "start_date": "2000-11",
      "completion_date": "2005-06",
      "has_results": false,
      "last_update_posted_date": "2006-08-18",
      "last_synced_at": "2026-07-23T17:08:07.753Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00087828"
    },
    {
      "nct_id": "NCT00101972",
      "title": "RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "monoclonal antibody RAV12",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MacroGenics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2004-12",
      "completion_date": "2008-05",
      "has_results": false,
      "last_update_posted_date": "2022-02-22",
      "last_synced_at": "2026-07-23T17:08:07.753Z",
      "location_count": 5,
      "location_summary": "Santa Monica, California • Washington D.C., District of Columbia • Miami, Florida + 2 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00101972"
    },
    {
      "nct_id": "NCT04402957",
      "title": "LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID",
        "Severe Acute Respiratory Syndrome",
        "Sars-CoV2",
        "Acute Kidney Injury",
        "Acute Respiratory Distress Syndrome"
      ],
      "interventions": [
        {
          "name": "LSALT peptide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arch Biopartners Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 61,
      "start_date": "2020-10-14",
      "completion_date": "2022-06-02",
      "has_results": true,
      "last_update_posted_date": "2025-07-09",
      "last_synced_at": "2026-07-23T17:08:07.753Z",
      "location_count": 3,
      "location_summary": "San Diego, California • Fort Lauderdale, Florida • Shreveport, Louisiana",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04402957"
    },
    {
      "nct_id": "NCT04831801",
      "title": "OAB and the Microbiome",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Overactive Bladder",
        "Urgency-frequency Syndrome"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 90 Years · Female only"
      },
      "enrollment_count": 39,
      "start_date": "2021-06-30",
      "completion_date": "2023-11-20",
      "has_results": false,
      "last_update_posted_date": "2024-05-21",
      "last_synced_at": "2026-07-23T17:08:07.753Z",
      "location_count": 2,
      "location_summary": "Fort Lauderdale, Florida • Miami, Florida",
      "locations": [
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04831801"
    },
    {
      "nct_id": "NCT00909181",
      "title": "Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Urge Urinary Incontinence",
        "Urinary Frequency"
      ],
      "interventions": [
        {
          "name": "Oxybutynin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Antares Pharma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 626,
      "start_date": "2009-03",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2014-07-02",
      "last_synced_at": "2026-07-23T17:08:07.753Z",
      "location_count": 55,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Laguna Hills, California + 50 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00909181"
    },
    {
      "nct_id": "NCT03934736",
      "title": "HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "End Stage Renal Disease on Hemodialysis (Diagnosis)"
      ],
      "interventions": [
        {
          "name": "HEPLISAV-B®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dynavax Technologies Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 119,
      "start_date": "2019-04-22",
      "completion_date": "2021-09-15",
      "has_results": true,
      "last_update_posted_date": "2024-08-09",
      "last_synced_at": "2026-07-23T17:08:07.753Z",
      "location_count": 20,
      "location_summary": "Bloomfield, Connecticut • Middlebury, Connecticut • Hollywood, Florida + 17 more",
      "locations": [
        {
          "city": "Bloomfield",
          "state": "Connecticut"
        },
        {
          "city": "Middlebury",
          "state": "Connecticut"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03934736"
    },
    {
      "nct_id": "NCT05410509",
      "title": "\"Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)\"",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Renal Cell Carcinoma (RCC)"
      ],
      "interventions": [
        {
          "name": "Trans-arterial embolization (TAE)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2024-01-03",
      "completion_date": "2025-11-19",
      "has_results": false,
      "last_update_posted_date": "2026-06-29",
      "last_synced_at": "2026-07-23T17:08:07.753Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • Stanford, California • Rochester, Minnesota + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05410509"
    }
  ]
}